Syneos Health to Present at the 41st Annual J.P. Morgan Healthcare Conference 2023/01/03 21:31:00 GlobeNewswire
MORRISVILLE, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. EST. The Company will not be hosting investor meetings.
Syneos Health Inc. (NASDAQ: SYNH) Down -65.16% This Year: What To Expect Next 2022/12/26 14:30:00 Stocks Register
The trading price of Syneos Health Inc. (NASDAQ:SYNH) closed higher on Friday, December 23, closing at $35.77, 1.05% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $35.00 and $35.79. The company’s P/E ratio in the trailing 12-month period was 12.95, while its 5Y … Syneos Health Inc. (NASDAQ: SYNH) Down -65.16% This Year: What To Expect Next Read More »
Clinical Trials Market Worth $52.0 Billion, Global Update, Share Analysis, Leading Players, Business Opportunities, Forecast by 2026 2022/12/15 16:16:00 SBWire
In September 2021, Syneos Health entered into a strategic collaboration with Ride Health to offer non-emergency medical transportation (NEMT) for clinical trial participants. Northbrook, IL 60062 -- ( SBWIRE ) -- 12/15/2022 -- The Global Clinical Trials Market by Phase (Phase I, II, III), Service Type (Site Identification, Laboratory Services, Decentralized Clinical Trial), Therapy Area (Oncology, Infectious Disease), and Application (Vaccines, Cell & Gene Therapy) - Global Forecast to 2026" published by MarketsandMarkets, the clinical trials market is projected to reach USD 52.0 billion by 2026 from USD 38.7 billion in 2021, at a CAGR of 6.1% during the forecast period. Factors such as growing R&D expenditure, increasing outsourcing of R&D activities, and the rising number of clinical trials worldwide are driving the growth of the global clinical trials market. The growing biosimilars and biologics market, rising demand for specialized testing services, and emerging Asian markets also offer significant growth opportunities for players operating in the market.
Syneos Health Extends Partnership with Medable 2022/12/13 12:30:00 GlobeNewswire
Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient
Syneos Health Adds HUB Patient Suite to Deployment Solutions Business 2022/10/27 11:30:00 GlobeNewswire
Brings Together the Industry’s Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from Prescription to Adherence Brings Together the Industry’s Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from Prescription to Adherence
Syneos Health Schedules Third Quarter 2022 Earnings Call for Friday, November 4, 2022 2022/10/21 20:30:00 GlobeNewswire
MORRISVILLE, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2022 financial results on Friday, November 4, 2022, prior to its earnings call at 8:00 a.m. ET.
Syneos Health downgraded to Neutral at JPMorgan on outlook 2022/10/18 12:00:14 Seeking Alpha
The shares of Syneos Health (SYNH) traded lower in the pre-market Tuesday JPMorgan downgraded the Contract Research Organization to Neutral from Overweight, citing uncertainty over…
2022 Leaders in Diversity Awards: Syneos Health 2022/10/14 02:00:00 Business Journals
Meet the outstanding winners in Triangle Business Journal''s 2022 Leaders in Diversity Awards!
How did Syneos Health Inc. (SYNH) fare last session? 2022/10/07 12:24:00 US Post News
In Thursday’s session, Syneos Health Inc. (NASDAQ:SYNH) marked $50.06 per share, down from $51.30 in the previous session. While Syneos Health Inc. has underperformed by -2.42%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SYNH fell by -41.86%, with highs and lows ranging from $104.18 to […]
Syneos Health, Inc. (NASDAQ:SYNH) Shares Purchased by Squarepoint Ops LLC 2021/10/31 15:22:43 Dakota Financial News
Squarepoint Ops LLC increased its holdings in shares of Syneos Health, Inc. (NASDAQ:SYNH) by 46.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 120,468 shares of the companys stock after purchasing an additional 37,990 shares during the quarter. Squarepoint Ops LLC owned 0.12% 
Virginia Retirement Systems ET AL Buys New Shares in Syneos Health, Inc. (NASDAQ:SYNH) 2021/10/24 10:26:46 Transcript Daily
Virginia Retirement Systems ET AL bought a new position in Syneos Health, Inc. (NASDAQ:SYNH) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 2,400 shares of the companys stock, valued at approximately $215,000. Other large investors also recently bought and sold shares of the company. FMR LLC lifted 
Healthcare Staffing Market to See Huge Growth by 2026 | Syneos Health, TeamHealth, Jackson Healthcare 2021/10/22 19:42:00 iCrowdNewswire
A Latest intelligence report published by AMA Research with title Healthcare Staffing Market Outlook to 2026. A detailed study accumulated to offer Latest insights about acute features of the Global Healthcare Staffing Market. This report provides a detailed overview of 
Silvercrest Asset Management Group LLC Has $22.75 Million Stock Holdings in Syneos Health, Inc. (NASDAQ:SYNH) 2021/10/22 16:20:42 Dakota Financial News
Silvercrest Asset Management Group LLC reduced its position in shares of Syneos Health, Inc. (NASDAQ:SYNH) by 1.5% during the second quarter, Holdings Channel reports. The institutional investor owned 254,185 shares of the companys stock after selling 3,763 shares during the period. Silvercrest Asset Management Group LLCs holdings in Syneos Health were worth $22,747,000 as of